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and only one survived. Appache II score 40 or more was observed in 4
patients and all died.
Conclusions: Pre-admission antibiotic treatment can reduce the probability
of death in patients with meningococcal disease. Niklasson score 5 or 6 and
Appache II score 40 or more are nearly connected with severe course of
disease.
Grant support: Grant Agency Czech Republic N. 3lU/96/K102.
IMoP373I Study of the intestinal opportunistic protozoal
infections in children
N. Andreeva', R. Kurdovi, V. Blagoeva', D. Popov', A. Stoianova'
IHigher Medical IllStitute, Plovdiv; 2N CIPD, Sofia, Bulgaria
Objectives: The present study is aimed at comparing the prevalence rate and
structure ofprotozoal opportunistic infections in immunocompromised and
immunocompetent children. The study includes a total of919 patients - 52
children with malignant diseases (leukemias, lymphomas, Ewing-, osteo-
and soft tissue sarcomas, meduloblastomas), undergoing intense chemother-
apeutic regimens (in them no diarrhoeal episodes are observed in the course
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rwe--o1] Divergence in the Bordetella pertussis virulence
factors pertactin and pertussis toxin in dinical isolates in the
U.K.
N. K. Fry', S. Neal', Y. T. Li', T. G. Harrison'. E. Miller', R.
Matthews3, R. C. George'
IpHLS Cell/ral Public Healtll Laboratory; 2pHLS Communicable Disease
Surveillance Cenlre, London; 3Pertussis Rejerfllce Laboratory, University of
Manchester, Manchester, United Kingdom
Objectives: To determine the antigenic variation in two important viru-
lence factors of Bordetella pertussis, pertactin and pertussis toxin, in clinical
isolates in the U.K. from 1920 to 1999.
Methods: The DNA sequence ofvariable regions of the genes for pertactin
(prn) and the pertussis toxin SI subunit were determined by PCR amplifica-
tion and direct sequencing.
Results: The pertactin type of all historical U.K. strains from 1920 to 1968
was identical (100% prnl) and identical to those included in the Wellcome/
Medeva Pharma whole cell vaccine (WCV) used in the U.K. Variants have
emerged which are not represented in this WCV among isolates from 1977
to 1986 (n = 78),77% prnl, 19% prn2 and 4% pm3. The frequency ofpm
types among recent isolates from 1998/99 (n = 99) is 50% prnl, 47% prn2
and 3% prn3. Analysis of the B. pmussis pertussis toxin SI gene (sl) revealed
two variants designated 51 A and siB. The frequency of historical isolates
from 1920 to 1968 (n = 50) was 60% 51 A and 40% 51B. In isolates from 1977
to 1986 (n = 43) the frequency changed to 95% sIAand5%sIB. Among the
most recent isolates tested from 1998/99 (n = 80) only the type slA has been
found (100%, sIA).
Conclusions: These data are consistent with the theory that vaccination in
the U.K. has selected for strains which are antigenically distinct from vaccine
strains. Surveillance of the variation of these antigens between circulating
and vaccine strains of B. pertussis in the U.K. will be important, particularly
with the replacement of current WCVs with acellular pertussis vaccines.
IWe021 'Variant-peptides' elicit CD8+ T-eells directed against
HPV16-E7 epitopes
K. Nilges', K. Freitag', H. Pilch2, S. Giinzel2 , C. Neukirch', H. Hohn',
M. Maeurer'
Depts. of t Med. Mitrobiology; 2Cynecology, University ofMainz, Germany
Objectives: 1) To evaluate if T-cells directed against HPV16-E7 epitopes
recognize related peptidcs of distinct origin ('mimicry'), and 2) if pcrmu-
tated variant peptides are able to induce a strong and effective T-cell response
directed against naturally processed and HLA-A2 presented peptides on
cervical cancer cells.
of study); 455 children without gastrointestinal complaints treated as out-
patients and 412 clinically healthy children from rural day-care centers.
Methods: Fresh stool samples are collected from each patient and are tested
twice: 1. by microscopy ofsaline wet and iodine stained slides and by Ziehl-
Nielsen stained slides. 2. By culturing in Pavlova's medium. Part of the
samples are tested by Monofluo-kit Cryptosporidium (Diagnostics Pasteur).
Results: Opportunistic protozoal infections arc established in all study
groups - their prevalence rates are as follows: 36.5% (highest) in children
with malignant diseases (immunocompromised), 13.4% in the outpatients
and 5.8% (lowest) in children from rural day-care centers. Cryptosporidium
spp is also detected in all groups with infestations rates being: 15.4%,0.6%
and 3.9% respectively. B. hominis is present in 11.5%. 5.7% and 0.2% of the
children respectively, G. lamblia - 9.6%, 7.0% and 1.7% respectively. B.
IlOminis and G. lamblia are present concurrently in one case (in immuno-
compromised).
Conclusions: In immunocompromi.sed children a high incidence ofasymp-
tomatic intestinal opportunistic infections is established. They, if not
properly diagnosed and adequately treated are not only epidemiologically
dangerous but present a serious risk of heavy. even fatal, diarrheal condi-
tions.
Methods: T-cell reactivity directed against a panel of variant peptides was
measured in PBL obtained from HLA-A2 + healthy volunteers or from
women with cervical cancer. The 'qualiry' ofthe CDB- T-cell response was
evaluated by spectratyping of the T-cell receptor (TCR) CDR3-region
using DNA-fragment analysis. Expansion of individual TCR-families was
tested using a panel of21 mAbs directed against the TCR beta chain. After in
vitro stimulation with variant peptides, T-cells were cloned and tested for
peptide and tumor recognition as determined by cytotoxicity and cyrokine
(GM-CSF, IFN')') release.
Results: 'Crossreactive' T-cells exist which define the naturally processed
and HLA-A2 presented HPVI6-E7-peptide on tumor cells and closely
related peptide species of human or viral origin.
Condusions: 1) Variant peptides may be useful in order to drive an effective
immune response against HPV in patients with cervical cancer 2) The T-cell
repertoire in patients with cervical cancer may be tolerant to HPV-peptide
epitopes due to 'mimicry' of closely related peptides species encountered
during other viral infections.
IWe031 An effective vaccine for Lyme borrellosis worldwide
B.J. Luft', L. Grubhofferz, R.J. Dattwyler', N. Rudenk02, X. Yangl,J.
J. Dunn3
IState Ulliversity o..fNew York, Stony Brook, NY, United States; 2IIlstitute of
Parasitology Czech Republic; 3Brookhavttl Natiollal Lab, Upton, NY, United
States
Objective: To design an effective vaccine for Lyme borreliosis in Europe
and Asia.
Methods: We delineated the protective epitopes of OspA and bioengi-
neered the protein to create a chimeric protein which contained polypeptides
from the OspA of Borrelia burgdorferi and Borrelia afzelli such that the
overall conformation of the immunoprotective epitopes were maintained.
We tested its immunogenicity and protective effects in a tick-murine model
of infection with ticks isolated from New York and the Czech Republic
which contained all three pathogenic genospecies.
Results: Mice immunized with the chimeric antigens had a remarkable and
significandy (p < 0.(01) higher antibody response to the OspA from various
genospecies than mice immunized with the OspA derived from a single
genospecies as measured in both cytototoxicity and ELISA assays. Chimer
immunized mice « (1.001) were fully protected (0/10 infected) against
challenge with ticks isolated from the Czech Republic which were infected
with Borrelia burgdorferi, Borrelia garinii, and Borrelia afzelii or ticks
isolated in New York (0/1 0 infected) compared to sham vaccinated controls
(18/20 infected).
Conclusions: Our studies demonstrate that this novel chimeric OspA
vaccine generate antibody with a broad range of specificity and provides
protection against all pathogenic genospecies of Borrelia that cause Lyme
borreliosis. This vaccine is an important candidate in providing protection
against Lyme borreliosis worldwide.
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[Wi04] Antibodies against a S. aureus fibronectin binding
peptide protect rats against endocarditis
A. Rennermalrnl , F. Brennan2,j. -I. Flockl
lDept ojClinical Bacteriology, Karolinska IllStitlltet, Hllddinge, Swedm;
2Microscietlce, London, Uniled Kingdom
ObJectives: To assess the protective efficiency of antibodies against a non-
binding form of a S. allreus fibronectin binding protein.
Methods: Rats were immunised with a recombinant cowpea mosaic virion
(CPMV). displaying a fibronectin binding domain (FnBP) from S. aureus.
on its capsid surface (CPMV-D). A truncated form of the fibronectin
binding peptide was used, thereby loosing its binding properties. QS21
was used as adjuvant. The immunised rats were subjected to a coupled
arthritis-endocarditis experimental infection: One week after induction of
septic arthritis in a temporomandibular joint, the aortic valve was damaged
by catheterisation. Bacteremia resulting from the arthritis thcn adhered to
the aortic vegetations which led to endocarditis.
Results: A hundred-fold lower recovery ofbacteria was found on the aortic
valves from rat, immunised with CPMV-D compared to control immu-
nised rats (p < 0.05). A reduced amount of bacteria were found also in
kidneys. Antibodies against CPMV-D were able to interfere with the
interaction between fibronectin and FnBP. S. allrells opsonised in vitro
with CPMV-D antibodies stimulated neutrophil activity to a higher extent
than controls. High specific antibody titres were detected.
Conclusions: Immunisation with a truncated non-binding peptide derived
from S. aureus FnBP, carried by the cowpea mosaic virus, results in high
titers of specific antibodies wich gave protection against infection with S.
allreus and could stimulate neutrophil activity in vitro.
IWeOSI CpG motif as adjuvant in polysaccharide conjugated
vaccines
C. von Hunolstein, R. Teloni, S. Mariotti, S. Recchia, G. Orefici, R.
Nisini
Lab. BMM, IstilUIO Sllperiore di Sanita Roma, Ilaly
Objectives: To investigate the role of synthetic oligodeoxynucleotides
containing CpG motifs (immunostimulatory sequences: ISS) as adjuvants
in the immune response to conjugated polysaccharide (CHO) vaccines.
Methods: Balb/c or COl mice were treated with two different protein
conjugated CHO from Haemophilus inJlufllzae type b (Hib) (2.5 /-Lg/mouse)
both in the presence and in the absence of ISS as adjuvant. Mice were
immunized twice, 14 days apart, when the tetanus toxoid (TT)-Hib
conjugated was used, and three times, 10 days apart, when using the cross
reacting material (CRM)-Hib, for intradermal route. ISS was mixed with
the vaccine at 50 /-Lg/mouse and used only in the first immwIization. Anti
CHO, anti-TT and anti-CRM specific Ig and IgG subclass levels were
determined by ELISA, as well as serum cytokine concentration. Tetanus
toxin neutralizing activity was determined by in vivo challenge. Diphtheria
toxin neutralizing activity was determined in vitro, using VERO ceU
viability.
Results: Anti-CHO specific antibodies significantly increased in the pre-
sence of ISS, both with tetanus (TT) and diphtheria (CRM) toxoid-
conjugated CHO vaccines. The adjuvant effect was also observed for the
immune response against the carrier protein (TT and CRM). ISS insured an
early and long lasting specific IgG production. The analysis of anti-CHO
IgG subclasses showed a significant increase of IgG2a and IgG3 in the
presence of ISS. ISS caused a rapid release ofIL-12 and IFN')' in sera from
treated mice. A single dose ofCHO-TT vaccine with, but not without, ISS
protected mice from a lethal dose of tetanus toxin, with efficiency compar-
able to that of anti-tetanus vaccine. The efficacy in neutralizing diphtheria
toxin ofsera from mice vaccinated with CHO-CRM in the presence ofISS
was shown using the diphtheria toxin sensitive VERO cell line.
Conclusions: These data provide a first demonstration that ISS have the
potential to increase host antibody response against both the CHO and the
protein component of a conjugated vaccine.
IWe061 Cytokine profile after measles vaccination: A pilot
study
K. Reid, Y. Sohni, I. Ovsyannikova, R.]aeobson, G. Poland
Mayo Vartine Research Grollp, Rorhesttr, MI, United States
Background: Integral to cytokines being used as markers of immune
response or vaccine adjuvants is an understanding of the cytokine secretion
pattern in response to vaccination.
Objectives: The aims of this pilot study were to determine when the peaks
ofIFN-g, IL-2, IL-4, IL-6 and TNF-a secretion occurred foUowing measles
vaccination in two groups of vaccinees.
Methods: Fifty-five healthy children were enrolled. Group I consisted of12
to 15 month olds presenting for their first measles vaccination (N = 15) and
Group 2 consisted of 4 to 12 year olds presenting for their second measles
vaccination (N = 40). Subjects were randomized to undergo phlebotomy
once on either day 0 (prior to vaccination) or day 2,5,10, 15,20,30 or 40
after receiving measles monovalent vaccine (Attenuvax, Merck). Super-
natants ofcultured PBMCs were assayed for cytokines by ELISA (Biotrak,
Amersham Pharmacia) after stimulation with PHA.
Results: Median cytokine levels for Group 1 revealed that IL-2, IL-6 and
IFN-g peaked on day 30, increasing from 155 to 355 pg/mL, 239 to 436 pgl
mL, and 28 to 62 pg/mL respectively. TNF-a decreased early, but increased
to baseline levels on days 20 and 30. For Group 2, IL-2 increased from 15 pgl
mL on day 0 to 451 pg/mL and 330 pg/mL on days 2 and 15 respectively.
IFN-g increased from 54 pg/mL on day 0 to 127 pg/mL and 118 pg/ml on
days 2 and 15 respectively. lL-6levels increased steadily from 140 pg/mL on
day 0 to 528 pg/mL on day IS, declined to 32 pg/mL on day 20, then
increased to 660 pgjmL on day 30. TNF-a peaked on day 15 (25 pg/mL on
day 0 to 335 pg/mL). For both groups IL-4levels were undetectable.
Conclusion: FoUowing measles vaccination, there appears to be two differ-
ent cytokine secretion patterns: an early (day 2-15) increase in both Tht and
Th2 cytokines in previously vaccinated children, with late peaking (day 30)
in previously unvaccinated children.
IWe071 Immunogenicity of two doses of a vlrosome
formulated hepatitis A vaccine administered 18 to 56 months
apart
B. Beck', C. Hatzl , R. Bronnimann2, R. Gliick2, C. Herzog2
1Swiss TropicallllSlitute, Basel; 2Swiss St'TUm & Vaccine Instituk, Berne,
Switzerland
Objectives: In order to confer long-lasting protection against hepatitis A ( >
20 years) it is recommended to give two doses of the aluminium-free,
virosome formulated hepatitis A vaccine (500 RIA units) 12 months apart.
Many travelers do not return in time for the 2nd dose. The objective of this
study was to assess the booster response to the vaccine in adult travelers > I
= 18 months after priming.
Methods: In an open, uncontroUed study 115 healthy travelers aged > I
= 18 years were enroUed and received a booster dose of the hepatitis A
vaccine 18 to 56 months after priming with a single Lm. injection. Serum
anti-HAV antibodies were determined at baseline (BL) and 1 month later by
EIA (ENZYMUN Boehringer). Safety was assessed at BL and for 4 days
after immunisation.
Results: Fifteen subjects who presented at BL with antibody titeres of >
7000 mlU/ml (suggestive of natural infection prior to basic immunisation)
were excluded from analysis. At BL 90.8% and 73.5% of the evaluable 98
subjects had antibody titers of> 1= 10 and> 1=20 mlUjml, respectively.
After boosting all subjects seroconverted to > 1= 20 mlU/ml with the GMT
raising from 41 to 2488 mlU/ml, a 6O.7-fold increase. In a subgroup it was
shown that on day II already one third of the final peak titer was reached.
Results will be presented in function ofthe length ofthe interval, as weU as of
age and gender. The vaccination was well tolerated.
Conclusions: The immunogenicity ofa booster dose ofthe aluminium-free,
virosome formulated hepatitis A vaccine is basicaUy not influenced by the
length of time interval since priming up to 4.7 years earlier.
IWeOSI Use of a virosome formulated hepatitis Avaccine in
6-7 month old infants and 5-7 year old children in Uthuania
R. VaIentelisl , V. Usonis2, V. Bakasenasl , G. Katilienel , D. Vidzenienel ,
R. GlUck3, C. Herzog3
IRepllbliran Immllnisation Celller; 2Center ofPediatrirs of Vi In ills UniversilY,
Vilnius, Lithuania; JSwiss Serum & Vaccine Institllte, Berne. Switzerland
Objectives: To evaluate the immunogenicity of an aluminium-free, viro-
some formulated hepatitis A vaccine (500 RIA units) in infants aged 6-7
months, as compared to children aged 5-7 years.
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Methods: In an open, uncontrolled study 30 infants and 30 children received
without prior screening vaccine doses intramuscularly at baseline (BL) and at
month 12. Safety was assessed for 4 days after the immunisations. Serum
anti-HAV antibodies were determined by EIA (ENZYMUN Boehringer)
at BL, on day 29, and at months 12 and 13.
Results: Fourteen infants had maternal antibodies (Mat-Ab) at BL (20-580
mIU/ml) and on day 29; 16 were seronegative « 20 mlU/ml) at BL.
Seroprotection (> 1= 20 mlUIml) was achieved by 1()()% of seronegative
infants and all children on day 29 (GMT: 169 and 126 mIU/ml). All infants
and children remained seroprotected until month 12 (GMT: 134 and 108
mIU/ml) and responded strongly to the booster (GMT: 2268 and 2541 mlU1
ml). The infants whithout Mat-Ab at BL had higher titers at month 12
(GMT: 180 vs 102 mlUIml) and responded significantly better to the booster
(GMT: 4341 vs 1185 mlU/ml). Vaccination was well tolerated.
Conclusions: Infants and children can safely and successfully be vaccinated
against hepatitis A from age 6 months on. Despite a negative interference by
Mat-Ab on the antibody titers achieved, the marked booster reponse
suggests that the infants were primed regardless of the presence of Mat-Ab.
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IWeP284!lmmunogenicity and tolerability of a preservative-
free influenza vacdne
A. Banzhoff, C. Schwenke, M. Broker
Chirotl Vaccines, Chiron Behring GmbH & Co, Marburg, Germany
Objectives: Recently, US and European regulatory authorities and vaccine
manufacturers have agreed to remove organomercuric preservatives from
vaccines based on a new benefit/risk evaluation. We have therefore inves-
tigated the immunogenicity and tolerability of the novel preservative-free
inactivated influenza vaccine Begrivaci'.'.
Methods: In a prospective study, carried out in autumn 1998, efficacy was
evaluated by the increase of influenza virus antibody titres from baseline to
21 days after vaccination. A total of 120 subjects were enrolled: 61 aged 18-
59 (adults) and 59 aged $;60 years (elderly). The safety variables included
local and systemic reactions and all adverse events. The antibody titres were
determined by hemagglutinin-inhibition assay.
Results: All three of the European efficacy requirements for influenza
vaccines, namely the seroconversion rate, the protection rate and the
conv"rsion factor. w"re met by the new preservative-free vaccine described
in this report for the thrcc stains. The mean geometric increase and the
proportion of vaccination responders were greater in patients of the adult
group than in the elderly. 53% ofthe subjects reponed local reactions such as
pain, erythema and induration, or systemic reactions such as headache and
fatigue.
Condusions: The present study demonstrates that the novel preservative-
free influenza vaccine is efficacious, retains its good tolerability profile and is
in accordance with the European requirements for influenza vaccines. This
new preservative-free influenza vaccine may contribute to increase the
compliance and lead to a higher vaccination rate.
IWeP28S1 safety and immunogenicity of a subunit influenza
vacdne
M. Minutello', A. Gruppioni2, I. Bastianoni', E. Montomole, R.
Gasparini3 , A. Podda
'Chiron Vaaines, Siena; 2ASL Vignola, Modena; JInst. ofHygiene, Univ. of
Siena, Italy
Objectives: To evaluate safety and immunogenicity of a subunit influenza
vaccine (formulation 1999-2000) in a population of young and elderly
people. .
Methods: Fifty-two adult subjects ($;60 years) and fifty-five elderly subjects
(> 60 years) received one dose of the Chiton subunit influenza vaccine
(AGRIPPAL SI™) and were monitored for reactogenicity through day 6
post-immunisation and safety during the entire 21 day study period.
Single Radial Haemolysis (SRH) assay was used to test the immunogeni-
city. The criteria were those recommended by the European Community
Committee,
Results: The immunogenicity results are reponed in the following table:
A/(H3N2) A/(HINI) B
Requirement n/N % n/N % n/N %
Adults N = 52
Seroconversion
rate > 40% 30/52 57.7 29/52 55.8 33/52 63.5
Mean GMT
increase > 2.5 3.353 3.408 3.130
SeroprOle,:tion
44/52 84.6rate > 70% 37/52 7\.2 41/52 78.8
Eldcrly N = 55
Scroronvcnion
rate > 30% 24/55 43.6 19/55 34.5 34/55 61.2
Mean GMT
increase >2 2.603 2.325 2.960
Seroprotection
rate > 600/0 36/55 65.5 40/55 72.2 44/55 80.0
Conclusions: Agrippal SIS was demonstrated to be safe and highly immu-
nogenic. AcruaIly, all thc European Community Committee immunogell.i-
city criteria were met for the thrcc influenza strains.
IWeP28611naeased Immunogenicity of the MF59-adjuvanted
influenza vacdne
M. Minutellol , T. Pozzi2, F. Senatorel , R. Gasparini2, A. Poddal
Chiron Vaccilles, Clinical Research, 53100 Siena, Ild/y
Objectives: To compare safety and immunogenicity of the MF59-adju-
vanted influenza vaccine (FLUADS ) to a conventional influenza subunit
vaccine (AGRIPPAL SIS) in elderly subjects.
Methods: Three-hundred and eight outpatient elderly subjects (~65 years)
were randomly assigned to receive one dose ofFLUAD8 or AGRIPPAL
SIS and were monitored for any reaction and other adverse events through
day 6 post-immunisation and any medical problem during the entire study
period. A blood draw for immunogenicity was obtained at day 0 and 28 days
after immunisation.
Results: No safety differences between the study vaccines were found with
the exception of a higher percen~eof mild pain at the injection site in
subjects immunised with FLUAD . lmmunogenicity results are reported
below:
Hlvniahl~ FLUAD AGRIPPALSI
Antigen (n = 192) (n = 99)
Geometric mean titre B 102*** 70
(GMT) A/HINI 191 167
A/H3N2 103*** 55
% ofsubjects with B 35* 27
~ fourfold increase A/HINI 20** 11
A/H3N2 52***29
% ofsubjects with B 54*** 35
titre ~ 1/160 AjHINI 88 85
A/H3N2 51*** 34
*p :s; 0.05: **p :s; 0.01: ***P :s; 0.001
Condusions: Both study vaccines were shown to be safe. The adjuvanted
vaccine was clearly more immunogenic than the conventional influenza
vaccine; for this reason it should be preferred for immunisation of elderly
people, who have a higher risk of developing influenza and its related
complications.
IWeP281! Appropriate needle length for Influenza
immunization: Fat pad thickness and local adverse events In an
older population
M. Neisen. G. Poland, R. Jacobson, R. Vierkant, D. Brakke, G. Chatfield
Mayo Vaccine Research Group, Mayo Clitlic, Rochrster, MI, United States
Background: For adult influenza immunization, intramuscular injection is
recommended. Whether a 16 mm needle adequately reaches muscle in older
adults is unknown. The purpose of this study was to gather data on deltoid
fat pad thickness and to compare side dfects as a function of vaccine
deposition site.
